Business
Knight Therapeutics Reports Fourth Quarter and Year-End 2025 Results
Delivered record-high revenues, Adjusted EBITDA 1 , Adjusted EBITDA per shar e 1 ...
About this update from Knight Therapeutics, Inc.
[{"type":"text","content":"Knight Therapeutics Reports Fourth Quarter and Year-End 2025 Results\nDelivered record-high revenues, Adjusted EBITDA1, Adjusted EBITDA per share1 since inceptionGenerated record high cash flow from operations since inceptionProvides 2026 revenues guidance of $490 million to $510 million and adjusted EBITDA1 of approximately 15% MONTREAL, March 19, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (\"Knight\" or “the Company”), a pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its fourth quarter and year ended December 31, 2025. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified. 2025 Highlights Financial results Revenues were $450,088, an increase of $78,784 or 21% over the prior year. The increase was primarily driven by the incremental revenues from the Paladin and Sumitomo Transactions and the growth of our key promoted products, partly offset by declines in our mature and branded generic products, the termination of a non-strategic agreement in Colombia and the impact of hyperinflation2.Gross margin was 44% of revenues compared to 47% in prior year. The decrease was due to the impact of hyperinflation2 and the fair value adjustment on the inventory acquired in the Paladin transaction.Operating loss was $2,350 compared to an operating income of $7,397 in prior year.Net loss was $5,374, compared to a net income of $4,332 in prior year.Loss per share was $0.05, compared to an earnings per share of $0.04 in prior year.Cash inflow from operations was $68,957, an increase of $32,677 or 90% over prior year. Non-GAAP measures Adjusted Revenues1 were $452,351, an increase of $86,939 or 24% or an increase of $87,855 or 24% on a constant currency1 basis, primarily driven by the incremental revenues from the Paladin and Sumitomo Transactions and the growth of our key promoted products, partly offset by declines in our mature and branded generic products and the termination of a non-strategic agreement in Colombia.Excluding the Paladin and Sumitomo acquisitions, the key promoted portfolio delivered a growth of 12% on a constant currency1 basis and a three-year CAGR exceeding 20%.The growth products3 acquired in the Paladin and Sumitomo transactions grew by 68% in the second half comp...